For all voting questions, the health outcomes of interest are: overall survival, control of disease-related symptoms, and the avoidance or minimization of the burdens to patients associated with anticancer therapy. The comparator is the management that the patient would otherwise have received. **For the voting questions, use the following scale identifying level of confidence - with 1 being the lowest or no confidence and 5 representing a high level of confidence.**	Satya-Murti	Darling	Dmochowski	Fuller	Matuszewski	Mintzer	Moore	Potters	Schulman	Steinbrook	Raab	Maden	Sokoloff	Voting Member Average	Overall Average
1 How confident are you that there is adequate evidence to determine whether or not the use of autologous cellular immunotherapy treatment of asymptomatic or minimally symptomatic metastatic, castrate-resistant prostate cancer significantly improves:															
1 Low Confidence -2- 3 Intermediate Confidence -4- 5 High Confidence															
a. Overall survival?	3	3	3	4	5	4	4	4	4	3	5	5	5	3.70	4.00
b. Control of disease-related symptoms?	2	3	2	2	3	1	2	2	2	1	3	3	2	2.00	2.15
c. Avoidance or minimization of the burdens associated with anticancer therapy while maintaining overall survival and control of disease-related symptoms?	4	4	3	4	4	5	5	3	3	4	5	5	5	3.90	4.15

Note: Questions 2 -6 should be addressed only for those outcomes under question 1 where the panel is confident that there is at least intermediate confidence (mean vote of 2.5) that there is adequate evidence to make the determination of improvement.	Satya-Murti	Darling	Dmochowski	Fuller	Matuszewski	Mintzer	Moore	Potters	Schulman	Steinbrook	Raab	Madan	Sokoloff	Voting Member Average	Overall Average
2 *2. How confident are you that there is adequate evidence to conclude that autologous cellular immunotherapy treatment significantly improves overall survival in patients who are asymptomatic or minimally symptomatic who have metastatic, castrate-resistant prostate cancer?*															
1 Low Confidence -2- 3 Intermediate Confidence -4- 5 High Confidence	3	4	3	3	4	4	4	4	4	3	5	5	5	3.6	3.92

		Satya-Murti	Darling	Dmochowski	Fuller	Matuszewski	Mintzer	Moore	Potters	Schulman	Steinbrook	Raab	Madan	Sokoloff	Voting Member Average	Overall Average
3	*3. How confident are you that there is adequate evidence to conclude that autologous cellular immunotherapy treatment significantly improves control of disease related symptoms in patients who are asymptomatic or minimally symptomatic who have metastatic, castrate-resistant prostate cancer?*															
	1 Low Confidence -2- 3 Intermediate Confidence -4- 5 High Confidence														#DIV/0!	#DIV/0!
	Not answered due to a less than 2.5 score on 1B															

		Satya-Murti	Darling	Dmochowski	Fuller	Matuszewski	Mintzer	Moore	Potters	Schulman	Steinbrook	Raab	Madan	Sokoloff	Voting Member Average	Overall Average
4	4. How confident are you that there is adequate evidence to conclude that autologous cellular immunotherapy treatment significantly improves the avoidance of the treatment burdens (e.g., access, delivery, or side-effects) associated with anticancer therapy in patients who are asymptomatic or minimally symptomatic who have metastatic, castrate-resistant prostate cancer?															
	1 Low Confidence -2- 3 Intermediate Confidence -4- 5 High Confidence	4	4	3	5	4	1	3	3	2	2	4	4	4	3.10	3.31

		Satya-Murti	Darling	Dmochowski	Fuller	Matuszewski	Mintzer	Moore	Potters	Schulman	Steinbrook	Raab	Madan	Sokoloff	Voting Member Average	Overall Average
5	5. How confident are you that these conclusions are generalizable to unlabeled use in:															
	1 Low Confidence -2- 3 Intermediate Confidence -4- 5 High Confidence															
	A. Patients whose prostate cancer has not metastasized?	1	1	1	1	1	1	2	1	1	1	2	2	1	1.1	1.23
	B. Patients who have metastatic, castrate-resistant disease and symptoms more severe than minimally symptomatic?	1	1	1	1	2	2	2	2	1	1	1	1	1	1.4	1.31
	C. Patients who have metastatic prostate cancer who have not failed hormonal therapy?	1	1	1	1	2	1	2	1	1	1	2	2	1	1.2	1.31

		Satya-Murti	Darling	Dmochowski	Fuller	Matuszewski	Mintzer	Moore	Potters	Schulman	Steinbrook	Raab	Madan	Sokoloff	Voting Member Average	Overall Average
6	*6. How confident are you that these conclusions are generalizable to:*															
	1 Low Confidence -2- 3 Intermediate Confidence -4- 5 High Confidence															
	A. Community based settings?	5	4	3	3	4	4	5	5	4	4	5	5	5	4.1	4.31
	B. Patients belonging to groups that may have been under-represented in the enrolled clinical trial populations?	1	2	3	4	3	3	3	4	3	3	4	4	4	2.9	3.15